The companies will collaborate to advance-to-market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer.
Debiopharm will shoulder full responsibility for the development and commercialization of any products arising from the partnership, and pay Marina up to $25m based on predefined research and development milestones as well as royalties on the sales of products resulting from the partnership.
Debiopharm founder and president Rolland-Yves Mauvernay said Marina’s RNAi drug discovery engine and the pre-clinical work they have accomplished in developing a bladder cancer therapeutic are impressive.
Marina Biotech president and CEO Michael French said Debiopharm’s world class capabilities in clinical development, regulatory affairs and CMC make them a perfect partner to advance such a unique therapeutic agent.